- Replys to Correspondence Reply to correspondence on “Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B”
- Heejoon Jang, Won Kim
- DOI: 10.3350/cmh.2025.0533 [Epub ahead of print]
- Editorials Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B
- Heejoon Jang, Won Kim
- DOI: 10.3350/cmh.2025.0430 [Epub ahead of print]
- Original Articles Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
- Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon
- Clin Mol Hepatol. 2024;30(3):500-514.
- Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
- Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
- Clin Mol Hepatol. 2024;30(3):487-499.
- Editorials Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
- Heejoon Jang, Won Kim
- Clin Mol Hepatol. 2023;29(2):381-383.
- Original Articles Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
- Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim
- Clin Mol Hepatol. 2020;26(3):328-339.